F2G
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. F2G is based in the U.K., the U.S. and Austria.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.f2g.com
Related News
F2G receives complete response letter from FDA for New Drug Application for Olorofim for the treatment of invasive fungal infections; plans resubmission with additional data and analyses
F2G moves UK headquarters to MediaCity
F2G announces FDA filing acceptance of New Drug Application for olorofim for the treatment of invasive fungal Infections
F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.